Abituzumab is a humanized anti-integrin _V monoclonal antibody developed for the treatment of prostate cancer metastatic. Abituzumab binds to _V_3 and inhibits endothelial cell-cell interactions, endothelial cell-matrix interactions, and integrin-mediated tumor angiogenesis and metastasis in _V_3-expressing tumor cells.